EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer

Shengjuan Hu iD, Sicong Li iD, Yiyuan Cui, Ying Wang, Luyao Chen, Xiyuan Zhang, Li Hou, Li Feng

Cancers · 15.05.2026 · 18 (10) · 1608

DOI: 10.3390/cancers18101608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 15.05.2026. Verfasst von Shengjuan Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Small cell lung cancer (SCLC) carries a dismal prognosis with limited biomarkers for risk stratification. This study aimed to identify circulating prognostic biomarkers.

Methods

We prioritized SCLC risk-associated genes using Summary-data-based Mendelian Randomization of pQTL/eQTL, differential expression, and weighted gene co-expression network analysis. Five machine learning approaches were compared to develop a diagnostic model based on ACE, AGER, and IL18R1, trained on GSE149507 and validated in GSE60052. We conducted single-cell transcriptomic analysis using public datasets (GSE150766 and GSE279570) and peripheral blood mononuclear cells (PBMCs) from our extensive-stage cohort. Finally, prioritizing the lead candidate IL18R1, we enrolled a prospective clinical cohort to assess its prognostic utility. A LASSO–Cox prognostic model incorporating plasma IL18R1 and clinical variables was internally validated (7:3 split) for progression-free survival (PFS) prediction.

Results

Integrative multi-omics identified ACE, AGER, and IL18R1 as SCLC-protective genes. Elastic Net machine learning identified a two-gene predictive signature (AGER and IL18R1) with robust diagnostic accuracy. Single-cell RNA sequencing revealed the predominant downregulation of ACE, AGER, and IL18R1 in T cells and alveolar type II cells from SCLC patients. PBMC analysis further supported IL18R1 downregulation in CD8+ T cells, NK cells, and dendritic cells. In an independent prospective cohort (n = 300), lower plasma IL18R1 levels were independently associated with shorter PFS (HR = 0.997 per unit increase; 95% CI: 0.995–0.999; and p = 0.003), with time-dependent AUCs of 0.77–0.86. Performance in limited-stage disease was inconsistent and requires further validation. A prognostic model incorporating plasma IL18R1 and 11 clinical parameters stratified patients into distinct risk groups (HR = 5.19), showing a strong discriminative ability in extensive-stage SCLC.

Conclusions

We identified ACE, AGER, and IL18R1 as protective factors against SCLC progression. Integration of plasma IL18R1 with clinical parameters provides a prognostic tool for extensive-stage SCLC.

Schlagwörter

Stichwörter der Autor:innen

IL18R1biomarkermachine learningsingle-cell analysissmall cell lung cancer

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
  • Traditional Chinese Medicine Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
  • Department of Oncology, The Mongolia-Chinese Medical Hospital of Chifeng, Chifeng 024000, China.
  • The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 511436, China.
  • Beijing Key Laboratory of Digital Intelligence Traditional Chinese Medicine Oncology Prevention and Treatment, Beijing 100021, China.

ORCID-Profile: Shengjuan Hu, Sicong Li

Förderung

  • the National Key Research and Development Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Hu, S., Li, S., Cui, Y., Wang, Y., Chen, L., Zhang, X., Hou, L., & Feng, L. (2026). Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer. Cancers, 18(10), 1608. https://doi.org/10.3390/cancers18101608

Vancouver

Hu S, Li S, Cui Y, Wang Y, Chen L, Zhang X, et al. Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer. Cancers. 2026;18(10):1608. doi:10.3390/cancers18101608

BibTeX
@article{Hu2026,
  author = {Hu, Shengjuan and Li, Sicong and Cui, Yiyuan and Wang, Ying and Chen, Luyao and Zhang, Xiyuan and Hou, Li and Feng, Li},
  title = {Integrative Multi-Omics Analysis Identifies IL18R1 as a Circulating Prognostic Biomarker for Risk Stratification in Extensive-Stage Small Cell Lung Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1608},
  doi = {10.3390/cancers18101608}
}
Kostenlos starten →